Educational insights about GARD

When you watch our webinars, you will learn in what ways GARD is more relevant than animal testing and much more. We cover essential topics that range from genomics and machine learning, how the technology works, and why it is highly accurate and has such robust prediction for in vitro sensitization testing.

© SenzaGen

March 26, 2020
Web-based conference on “Difficult-to-test” substances and regulatory testing
By Andy Johansson, SenzaGen AB and guest speakers from Eurofins, Lubrizol and MB Research Labs

Key takeaways

  • Insights on sensitization assessment of “difficult-to-test” substances
  • Experiences on how to use GARD for regulatory testing
  • Results from industry partners from several applications and case studies
  • Updates on the GARD assays by SenzaGen experts

Session recordings
#1: Dr Andy Forreryd, SenzaGen
#2: Drs. Charles Humfrey/Yafan Li/Len Sweet: Collaborators at the Lubrizol Corporation (soon available)
#3: Helge Gehrke, Eurofins BioPharma Product Testing
#4: Dr. George DeGeorge, MB Research Labs

February, 2020

In vitro sensitization testing based on genomics and machine learning
By Angelica Johansson, SenzaGen AB

October, 2019

In vitro sensitization testing of Medical Devices – GARD skin Medical Device 
By Rose-Marie Jenvert, PhD, SenzaGen

September 2019

How are the in vitro GARD™ assays used in real life? – Cases and applications for testing of skin and respiratory sensitizers
By Andy Forreryd, PhD, SenzaGen

April 2019

Genomics and Machine Learning – All you need to know about the GARD™ technology for in vitro sensitization testing
By Andy Forreryd, PhD, SenzaGen

December 2018

In vitro testing for Respiratory Sensitizers using a genomic biomarker signature and the GARDtechnology platform
By Andy Forreryd, PhD, SenzaGen

May 2018

Sensitization testing and hazard assessment using functional genomics with GARD
By Henrik Johansson, PhD, SenzaGen